Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: David S. who wrote (3678)	1/26/1998 11:44:00 PM
From: JOHN W.	Read Replies (1) \| Respond to of 6136

Todays jump must have scared you since we have gone from mindless modem checks to very well researched, deliberate imaginations from a __________(fill in the blank). You have made this statement. That all of these products are the same in future competition for the Rhinovirus 3C inhibitor. Please prove it... You tried chicken soup, now this list... then soup idea had more merit!. David, you can do better... Even Mr. Pink dosen't believe you anymore...

To: David S. who wrote (3678)	1/27/1998
From: JOHN W.	Read Replies (1) \| Respond to of 6136

Elise Wang (1/26/98): "FAVORABBLE CROSS-RESISTANCE PROFILE AS DEMONSTRATED IN CLINICAL DATA: Abstract 510: Virologic response to a Ritonavir/Saquinavir containing regimen in patients who have previously failed Nelfinavir.. Time/Data: Slide Session 65 (Antiretroviral Chemotherapy II), 10:30-12:30pm, Wednesday, Febuary 8. Key Author: P. Tebas, Wsahington University, St. Louis, MO. This abstract presents data on a group of 27 patients who failed Viracept after achieving viral load suppression below levels of detection for at least 52 weeks. 100% of patients (19/19) who were originally protease inhibitor naive responded to the combination of Norvir/Invirase. 43% of patients (3/7) who were highly pre-treated and then failed Viracept still responded to this combination therapy. These results demonstrated that most patients who failed on Viracept responded to a switch to a combination regimen with Norvir/Invirase. This study is supported by a similiar conclusion described in another study presented in Abstract 427. These clinical data support our premise that Viracept represents the optimal first line therapy among protease inhibitors given its ability to generate less cross resistance."